Kymera Therapeutics (KYMR) Other Accumulated Expenses (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Other Accumulated Expenses data on file, last reported at $409000.0 in Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $409000.0, down 97.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $409000.0 (down 97.09% YoY), and the FY2025 annual result was $21.4 million, up 19.94% from the prior year.
• Other Accumulated Expenses fell to $409000.0 in Q1 2026 per KYMR's latest filing, from $21.4 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $21.4 million in Q4 2025 and troughed at $178000.0 in Q2 2024.
• A 5-year average of $6.5 million and a median of $1.5 million in 2023 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2025: Other Accumulated Expenses sank 98.0% in 2022, then surged 9265.17% in 2025.
• A 5-year view of Other Accumulated Expenses shows it stood at $303000.0 in 2022, then soared by 4883.17% to $15.1 million in 2023, then rose by 17.9% to $17.8 million in 2024, then climbed by 19.94% to $21.4 million in 2025, then slumped by 98.08% to $409000.0 in 2026.
• Business Quant data shows KYMR's Other Accumulated Expenses at $409000.0 in Q1 2026, $21.4 million in Q4 2025, and $14.6 million in Q3 2025.